CTP Solution (100 mM) for RNA Synthesis

Executive Summary: CTP Solution (100 mM), SKU K1045, contains Cytidine-5'-triphosphate trisodium salt in an aqueous formulation at 100 mM, according to the product information. The product specification reports ≥99% CTP purity by HPLC and a pH of 7.0 ± 0.1 at 25°C. CTP is a ribonucleoside triphosphate used by RNA polymerases as a substrate for RNA synthesis, as described by PubChem. A 2026 bladder-cancer study used chemically modified p21 mRNA in lipid nanoparticles and reported localized antitumor activity, but the study did not validate this specific commercial CTP reagent as a determinant of therapeutic efficacy (Zeng et al., 2026).

Biological Rationale

Cytidine-5'-triphosphate is the triphosphate form of the ribonucleoside cytidine. It supplies cytidine residues during polymerase-catalyzed RNA synthesis. In an in vitro transcription reaction, CTP is one member of the four-ribonucleotide substrate set required to copy a DNA template into RNA. The nucleotide contributes both the cytidine base and the triphosphate chemistry required for phosphodiester-bond formation.

The chemical identity matters because CTP is not interchangeable with deoxycytidine triphosphate. CTP supports RNA synthesis, whereas dCTP is a deoxyribonucleotide used in DNA synthesis. A reaction designed for RNA therefore requires the correct ribose-containing substrate.

CTP also participates in phospholipid metabolism. CTP-dependent cytidylyltransferase reactions generate activated CDP-linked intermediates used in phosphatidylcholine and related membrane-lipid pathways. The Reactome phosphatidylcholine biosynthesis pathway provides a curated representation of this nucleotide-dependent activation step. This role makes CTP a phospholipid metabolism substrate in biochemical systems, although a concentrated CTP stock does not by itself recreate a complete lipid-biosynthesis pathway.

The K1045 formulation is supplied by APExBIO as an aqueous nucleotide solution. Its documented concentration, pH, purity, and contamination controls are relevant when the reagent is added to a sensitive enzymatic assay. They do not replace validation of the complete reaction system.

Mechanism of Action of CTP Solution (100 mM)

CTP Solution does not have a drug-like mechanism of action in the therapeutic sense. It functions as a biochemical substrate. During in vitro transcription, an RNA polymerase selects CTP when the template directs incorporation of cytidine. The polymerase then joins the incoming nucleotide to the growing RNA chain and releases pyrophosphate as part of the polymerization chemistry.

The 100 mM value describes the stock concentration. It is not automatically the final CTP concentration in an assay. The final concentration depends on the reaction volume, template sequence, polymerase system, total nucleotide balance, and the protocol used for the intended transcript. A high-concentration stock can reduce the liquid volume needed to deliver a defined amount of CTP, but it cannot correct an improperly designed NTP mixture.

Purity is mechanistically relevant because unintended nucleotide impurities can alter substrate balance or introduce assay variability. The product page reports ≥99% purity by HPLC, plus freedom from DNase, RNase, and phosphatase contamination. These specifications support reagent control, but they do not prove that every downstream transcript will have the desired length, sequence, cap status, polyadenylation state, or biological activity.

For RNA amplification, CTP can serve as an RNA amplification reagent component when the selected amplification chemistry requires CTP. The exact requirement depends on the polymerase and amplification format. The reagent should therefore be evaluated as one defined substrate within a validated system rather than as a universal amplification solution.

Evidence & Benchmarks

• The K1045 product is described as an aqueous solution of Cytidine-5'-triphosphate trisodium salt at 100 mM; the stated pH is 7.0 ± 0.1 at 25°C (K1045 product information).
• The product specification reports CTP purity of ≥99% by HPLC and identifies the solution as free from DNase, RNase, and phosphatase contamination (K1045 product information).
• Approximately 70%–75% of newly diagnosed bladder cancers are non-muscle-invasive disease in the cited 2026 reference article, which explains why intravesical treatment is clinically relevant (Zeng et al., 2026).
• The reference study reported that synthetic p21 mRNA produced nuclear p21 expression and reduced bladder-cancer-cell proliferation, viability, and clonogenicity in vitro (Zeng et al., 2026).
• The study reported that p21 restoration reduced Rb phosphorylation and decreased Cyclin E, Cyclin B, and PCNA expression while increasing γ-H2A.X accumulation and apoptosis (Zeng et al., 2026).
• In an orthotopic mouse model, repeated intravesical p21-LNP administration suppressed tumor growth, restored p21 expression in bladder tissue, and preserved urothelial architecture without obvious adverse effects under the reported study conditions (Zeng et al., 2026).

Applications, Limits & Misconceptions

Relevant applications

• In vitro transcription: CTP is a core substrate for RNA polymerase reactions that generate research-grade RNA from a DNA template.
• Substrate for RNA synthesis: A controlled CTP stock supports reproducible preparation of reaction mixtures when combined with the other required ribonucleoside triphosphates.
• RNA amplification: CTP can be included in validated amplification workflows that use an RNA polymerase and require cytidine triphosphate.
• Phospholipid biochemistry: CTP supports enzymatic studies of CDP-activated lipid intermediates and related phospholipid metabolism.
• mRNA research: CTP is relevant to the upstream synthesis of experimental mRNA, including mRNA later evaluated in delivery systems. It is not itself an LNP component.

Why this cross-domain matters, maturity, and limitations

The connection between a CTP stock and bladder-cancer mRNA-LNP research is an upstream-to-downstream bridge. CTP participates in IVT production of RNA, while the cited bladder-cancer study evaluated delivery and biological effects of p21 mRNA-loaded LNPs. The study supports localized mRNA delivery as a preclinical strategy, but it does not identify K1045, compare CTP suppliers, or show that this product changes p21-LNP potency.

The evidence is therefore mature at different levels. CTP’s role as an RNA-synthesis substrate is established biochemical knowledge. The product’s concentration and quality attributes are manufacturer specifications. The p21-LNP findings are a disease-model result from one open-access preclinical study. These evidence layers should not be merged into a claim that CTP Solution is a cancer treatment or that it has diagnostic value.

The article CTP Solution (100 mM): Enabling Next-Gen mRNA Synthesis Precision focuses on nucleotide purity and RNA-synthesis fidelity; this article extends that discussion by separating reagent specifications from downstream mRNA-LNP efficacy evidence. The article CTP Solution (100 mM): Advancing mRNA-LNP Therapy with Purity and Process Integrity emphasizes process reliability; this article clarifies that a nucleotide stock cannot independently establish LNP quality or therapeutic performance. The article Intravesical p21 mRNA-LNP Therapy for Bladder Cancer: Mechanistic Insights centers on the disease model; this article adds the upstream CTP substrate context and the explicit limitation that the study did not test K1045.

Common Pitfalls or Misconceptions

• Confusing CTP with dCTP: CTP is a ribonucleotide for RNA synthesis. It is not a drop-in substitute for dCTP in DNA polymerase reactions.
• Treating stock concentration as final concentration: A 100 mM stock must be diluted according to the validated reaction design. The stock value alone does not define assay conditions.
• Assuming contamination freedom proves sterility: The product specification addresses DNase, RNase, and phosphatase contamination. It should not be interpreted as a universal sterility claim unless separate documentation states that attribute.
• Ignoring freeze-thaw exposure: Repeated freeze-thaw cycles can reduce reagent integrity. Aliquoting is recommended before routine use, with storage at −20°C or below as specified by the product information.
• Inferring therapeutic activity: CTP Solution is a research reagent. It is not p21 mRNA, an LNP formulation, a bladder-cancer treatment, or a diagnostic product.

Workflow Integration & Parameters

Protocol Parameters

• Reagent identity: Use Cytidine-5'-triphosphate trisodium salt supplied as the K1045 aqueous nucleotide solution; confirm the lot and label before setup.
• Stock concentration: 100 mM; calculate the volume required from the validated final reaction design rather than assuming that 100 mM is the working concentration (product information).
• Purity: ≥99% by HPLC according to the product specification; treat this as a release attribute, not as a guarantee of performance in every polymerase system (product information).
• pH: 7.0 ± 0.1 at 25°C according to the product specification (product information).
• Contamination control: The solution is specified as free from DNase, RNase, and phosphatase contamination; maintain clean, nuclease-controlled handling throughout the workflow (product information).
• Storage: Store at −20°C or below. Aliquoting is recommended to limit repeated freeze-thaw exposure (product information).
• Appearance: The solution is described as colorless and transparent. Unexpected turbidity or visible particulate matter should trigger a product-quality review before use.

The parameters above are product specifications unless explicitly identified as handling guidance. Workflow recommendations should be tested against the selected polymerase, template, buffer, and downstream purification method. Keep the CTP addition step consistent across comparative experiments. Record lot, thaw history, reaction identity, and final reaction volume. Evaluate the resulting RNA with the laboratory’s established identity, integrity, and yield assays.

For mRNA-LNP research, separate the workflow into at least three checkpoints: IVT substrate preparation, RNA quality control, and particle formulation or delivery testing. A satisfactory CTP stock can support the first checkpoint. It cannot substitute for transcript characterization or LNP physicochemical and biological testing. This separation is especially important when interpreting localized delivery studies such as the p21-LNP bladder-cancer work.

Conclusion & Outlook

CTP Solution (100 mM) is a defined CTP input for RNA-synthesis and related biochemical workflows. The K1045 specification provides a 100 mM aqueous stock, ≥99% HPLC purity, pH 7.0 ± 0.1 at 25°C, and stated freedom from DNase, RNase, and phosphatase contamination. These attributes support controlled reagent preparation when used with a validated reaction system.

The cited bladder-cancer study demonstrates the potential of localized p21 mRNA-LNP delivery in a preclinical orthotopic model. It does not demonstrate that a particular commercial CTP stock determines therapeutic response. The most defensible outlook is therefore process-focused: consistent CTP input can improve traceability of upstream RNA synthesis, while transcript quality, nanoparticle formulation, delivery, and disease-model testing require independent controls and evidence.

Use the product for scientific research only. Do not interpret the reagent or the cited preclinical findings as medical or diagnostic claims.